Cancer Stem Cell News Volume 11.17 | May 4 2022

    0
    33







    2022-05-04 | CSCN 11.17


    Cancer Stem Cell News by STEMCELL Technologies
    Vol. 11.17 – 4 May, 2022
    TOP STORY

    Integrated Analysis of Single-Cell and Bulk RNA Sequencing Data Reveals a Pan-Cancer Stemness Signature Predicting Immunotherapy Response

    Investigators revealed a robust link between cancer stemness and immunotherapy resistance and developed a promising signature, Stem.Sig, which showed increased performance in comparison to other signatures regarding immune checkpoint inhibitor response prediction.
    [Genome Medicine]

    Full Article
    Be sure the cells you’re gene editing are still HSPCs with StemSpan™ SFEM II culture medium.
    PUBLICATIONSRanked by the impact factor of the journal

    Galectin-1 Orchestrates an Inflammatory Tumor-Stroma Crosstalk in Hepatoma by Enhancing TNFR1 Protein Stability and Signaling in Carcinoma-Associated Fibroblasts

    Scientists uncovered a crucial role of Galectin-1 (Gal-1) in carcinoma-associated fibroblasts that orchestrated an inflammatory CSC niche supporting hepatocellular carcinoma (HCC) progression and demonstrated that targeting Gal-1 could be a potential therapy for fibrosis-related HCC.
    [Oncogene]

    Abstract

    Enhanced AC133-Specific CAR T Cell Therapy Induces Durable Remissions in Mice with Metastatic Small Cell Lung Cancer

    AC133+ cancer stem cells and PD-L1+CD73+ myeloid cells were detectable in primary human small cell lung cancer tissues, suggesting that patients may benefit from the triple-immunotherapy.
    [Cancer Letters]

    Abstract

    Antifouling Gold-Inlaid BSA Coating for the Highly Efficient Capture of Circulating Tumor Cells

    Circulating tumor cells were chosen as template biomarkers to verify the application of BGC-SW modified with sgc8-aptamer in various separation processes of untreated biofluids.
    [Analytical Chemistry]

    AbstractGraphical Abstract

    TDP43 Promotes Stemness of Breast Cancer Stem Cells through CD44 Variant Splicing Isoforms

    Investigators found that loss of TAR DNA-binding protein-43 (TDP43) inhibited breast CSC stemness by reducing the abundance of cluster of differentiation 44 (CD44) variant alternative splicing isoforms.
    [Cell Death & Disease]

    Full Article

    Immune Activation of the Monocyte-Derived Dendritic Cells Using Patients Own Circulating Tumor Cells

    New protocols for monocyte-derived dendritic cell (mMo-DC) production using automatization and circulating tumor cell lysates were introduced including a feasible in vitro assay for mMo-DC efficacy evaluation.
    [Cancer Immunology Immunotherapy]

    Abstract

    miR-2392 Functions as Tumor Suppressor and Inhibits Malignant Progression of Hepatocellular Carcinoma via Directly Targeting JAG2

    Circulating tumor cells were enriched from blood samples of hepatocellular carcinoma patients and cultured by 3D system.
    [Liver International]

    Abstract

    Analytical Validation and Initial Clinical Testing of Quantitative Microscopic Evaluation for PD-L1 and HLA I Expression on Circulating Tumor Cells from Patients with Non-Small Cell Lung Cancer

    Preliminary testing of circulating tumor cells isolated from patients with non-small cell lung cancer demonstrated heterogeneity in PD-L1 and HLA I expression and promising clinical value in predicting PFS.
    [Biomarker Research]

    Full Article

    miR-600 Promotes Ovarian Cancer Cells Stemness, Proliferation and Metastasis via Targeting KLF9

    Researchers suggested that miR-600 promotes ovarian cancer cell stemness, proliferation and metastasis via directly downregulating kruppel like factor 9 (KLF9), and impairing miR-600 levels may be a new treatment strategy for ovarian cancer in the future.
    [Journal of Ovarian Research]

    Full Article
    ON987CXN-may-728x90-2022
    REVIEWS

    Feed-Forward Loops between Metastatic Cancer Cells and Their Microenvironment—the Stage of Escalation

    The authors discuss in detail the importance of feed-forward loops of cancer cells with their microenvironment including the secretome, interaction with specialized tissue-specific cells, nutrients/metabolites, and that novel therapies should target not only the cancer cells but also the tumor microenvironment.
    [EMBO Molecular Medicine]

    Full Article

    Role of p38 MAP Kinase in Cancer Stem Cells and Metastasis

    P38 mitogen-activated protein kinase (p38 MAPK) was downstream of several CSC-specific signaling pathways, and it played an important role in CSC development and maintenance and contributed to metastasis and chemoresistance.
    [Oncogene]

    Full Article

    Similarities and Differences between Embryonic Implantation and CTC Invasion: Exploring the Roles of Abortifacients in Cancer Metastasis Chemoprevention

    Scientists investigate the multidisciplinary data from recent large epidemiological chemoprevention studies for long-term use of oral contraceptives to reduce cancer risk and differences in cellular and molecular processes between embryonic implantation to endometrium and adhesion/invasion of circulating tumor cells to vascular endothelium.
    [European Journal of Medicinal Chemistry]

    AbstractGraphical Abstract
    INDUSTRY AND POLICY NEWS

    NYU Administrators Defend David Sabatini, Challenge Sexual Harassment Findings

    The New York University (NYU) community was plunged into turmoil this week by the news that its Grossman School of Medicine is considering hiring prominent biologist David Sabatini, who had been forced out of jobs at the Whitehead Institute for Biomedical Research and the Massachusetts Institute of Technology for sexual misconduct.
    [New York University (Science)]

    Press Release

    Harpoon Therapeutics and Roche to Collaborate on Clinical Trials to Study Novel Immuno-Oncology Combination for Small Cell Lung Cancer

    Harpoon Therapeutics, Inc. announced that it has entered into a clinical supply agreement with Roche to supply atezolizumab for use in the Company’s HPN328, a DLL3 targeting TriTAC®, clinical development program.
    [Harpoon Therapeutics, Inc.]

    Press Release
    FEATURED EVENT

    ISSCR 2022 Annual Meeting

    June 15 – 18, 2022
    San Francisco, California, United States

    > See All Events

    JOB OPPORTUNITIES

    Scientific Officer – Cell Biology

    Institute of Cancer Research – London, United Kingdom

    Postdoctoral Position – Gynecologic Cancer

    Johns Hopkins University – Baltimore, Maryland, United States

    Associate Professor – Cancer Immunology

    McGill University – Montreal, Quebec, Canada

    Scientific Director – Cancer Research

    Cyprus Cancer Research Institute – Nicosia, Cyprus

    Tenure-Track Associate Professor – Stem Cell Biology

    The University of Hong Kong – Hong Kong, China

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Cancer Stem Cell News Twitter